An upstate New York pharmaceutical sales representative was among three whistle-blowers to supply information to federal prosecutors leading to a $193 million settlement with makers of the Lidoderm ...

Lidocaine patches could be an alternative pain solution. Lidocaine patches may be effective for patients who are in pain but are looking to avoid drugs that could be addictive. Whenever a patient ...

The results of this exploratory study suggest that Lidoderm can alleviate the pain associated with OA of the knee. "The results of this exploratory study suggest that Lidoderm can alleviate the pain ...

AUSTIN, TX—Arash Nafissi, DO, and colleagues of Hospital for Joint Disease, New York University, report that placing a topical Lidoderm patch provides an effective adjunct treatment in post-operative ...

CHADDS FORD, Pa., March 31, 2005 – Today at the 24th Annual Scientific Meeting of the American Pain Society, Endo Pharmaceuticals Inc. released new clinical trial data which found patients receiving ...

September 28, 2010 (Las Vegas, Nevada) — The use of a transdermal lidocaine 5% patch (Lidoderm, Endo Pharmaceuticals) benefits patients who have undergone unilateral knee replacement surgery by ...

PARSIPPANY, N.J. — Generic drug maker Watson Pharmaceuticals has entered a settlement that will allow it to launch a generic patch used to treat post herpetic neuralgia, a pain disorder associated ...

A preclinical study commissioned by Alliqua, Inc. (OTCQB: ALQA) ("Alliqua" or "the Company") concluded that the Company's investigational lidocaine transdermal patch compares favorably to the Lidoderm ...

NEW YORK (AP) -- Shares of Watson Pharmaceuticals climbed Friday after federal regulators approved its generic version of Endo Health Solutions Inc.'s Lidoderm pain patch. THE SPARK: Watson said its ...

Pharma has its latest pay-for-delay settlement. In a pair of deals with two plaintiff classes over generic Lidoderm delays, Endo, Teva and Japanese drugmaker Teikoku Seiyaku have agreed to fork over ...

BRIDGEWATER, N.J.--(BUSINESS WIRE)-- Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced that it has received Abbreviated New Drug Application (ANDA) approval from ...